Duloxetine for the treatment of stress urinary incontinence

References

• Hannestad YS, Rortveit G, Sandvik H, Hunskaar S. Norwegian EPINCONT study. Epidemiology of incontinence in the county of Nord-Trondelag. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. J. Clin. Epidemiol.53(11), 1150–1157 (2000).
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M et al. Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation subcommittee of the International Continence Society. Urology61(1), 37–49 (2003).
   PubMed Web of Science ®Google Scholar
• DeLancey JO. The pathophysiology of stress urinary incontinence in women and its implications for surgical treatment. World J. Urol.15(5), 268–274 (1997).
   PubMed Web of Science ®Google Scholar
• Hilton P, Stanton SL. Urethral pressure measurement by microtransducer: the results in symptom-free women and in those with genuine stress incontinence. Br. J. Obstet. Gynaecol.90(10), 919–933 (1983).
   PubMedGoogle Scholar
• Hay-Smith E, Dumoulin C. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst. Rev.25(1), CD005654 (2006).
   Google Scholar
• Bø K. Pelvic floor muscle exercise for the treatment of stress urinary incontinence. An exercise physiology prospective. Int. Urogynecol. J.6, 282–291 (1995).
   Google Scholar
• Bo K, Kvarstein B, Nygaard I. Lower urinary tract symptoms and pelvic floor muscle exercise adherence after 15 years. Obstet. Gynecol.105(5 Pt 1), 999–1005 (2005).
   PubMed Web of Science ®Google Scholar
• Bombieri L, Freeman RM, Perkins EP, Williams MP, Shaw SR. Why do women have voiding dysfunction and de novo detrusor instability after colposuspension? Br. J. Obstet. Gynaecol.109(4), 402–412 (2002).
   Google Scholar
• Kjolhede P. Long-term efficacy of Burch colposuspension: a 14-year follow-up study. Acta Obstet. Gynecol. Scand.84(8), 767–772 (2005).
   PubMed Web of Science ®Google Scholar
• Radley SC, Chapple CR, Mitsugiannis IC, Glass KS. Transurethral implantation of Macroplastique for the treatment of female stress urinary incontinence secondary to urethral sphincter deficiency. Eur. Urol.39, 383–389 (2001).
   PubMed Web of Science ®Google Scholar
• Cardozo L. Duloxetine in the context of current needs and issues in treatment of womenwith stress urinary incontinence. Br. J. Obstet. Gynaecol.113(Suppl. 1), 1–4 (2006).
   Google Scholar
• Cardozo L. Neurobiology of stress urinary incontinence: new insights and implications for treatment. J. Obstet. Gynaecol.25(6), 539–543 (2005).
   PubMedGoogle Scholar
• Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology25, 871–880 (2001).
   PubMed Web of Science ®Google Scholar
• Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J. Pharmacol. Exp. Ther.274(2), 1014–1024 (1995).
   PubMed Web of Science ®Google Scholar
• Fraser MO, Chancellor MB. Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence.BJU Int.91(8), 743–748 (2003).
   PubMed Web of Science ®Google Scholar
• Katofiasc MA, Nissen J, Audia JE, Thor KB. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci.71, 1227–1236 (2002).
   PubMed Web of Science ®Google Scholar
• Viktrup L, Bump RC. Pharmacological agents used for the treatment of stress urinary incontinence in women. Curr. Med. Res. Opin.19(6), 485–490 (2003).
   PubMed Web of Science ®Google Scholar
• Schuessler B. What do we know about duloxetine’s mode of action? Evidence from animals to humans. Br. J. Obstet. Gynaecol.113(Suppl. 1), 5–9 (2006).
   Google Scholar
• Duloxetine. Summary of Product Characteristics. Lilly (2006).
   Google Scholar
• Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J. Clin. Pharmacol.40(2), 161–167 (2000).
   PubMed Web of Science ®Google Scholar
• Castro-Diaz D, Palma PC, Bouchard C et al. Duloxetine Dose Escalation Study Group. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int. Urogynecol. J. Pelvic Floor Dysfunct. (2006) DOI: 10.1007/s00192-006-0256-x (Epub ahead of print).
   Google Scholar
• Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am. J. Obstet. Gynecol.187(1), 40–48 (2002).
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J. Urol.170(4 Pt 1), 1259–1263 (2003).
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck P, Abrams P, Lange R, Slack M, Wyndaele JJ, Yalcin I et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. Br. J. Obstet. Gynecol.111(3), 249–257 (2004).
   Google Scholar
• Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int.93(3), 311–318 (2004).
   PubMed Web of Science ®Google Scholar
• Yalcin I, Bump RC. The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence. Am. J. Obstet. Gynecol.191(1), 194–197 (2004).
   PubMed Web of Science ®Google Scholar
• Ghoniem GM, Van Leeuwen JS, Elser DM et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J. Urol.173(5), 1647–1653 (2005).
   PubMed Web of Science ®Google Scholar
• Mariappan P, Ballantyne Z, N’Dow JM, Alhasso AA. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database Syst. Rev. (3), CD004742 (2005).
   Google Scholar
• Algorithm for the initial management of women with urinary incontinence. Third International Consultation on Incontinence Meeting. Monte Carlo, Monaco, June 26–29, 2004.
   Google Scholar
• The Management of Urinary Incontinence in Women. Clinical Guidance. The National Institute of Clinical Excellence, London, UK (2006).
   Google Scholar
• Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet. Gynecol.104(3), 511–519 (2004).
   PubMed Web of Science ®Google Scholar